Moreover, there is evidence that inhibition of IDO1, TDO, and KMO or other interventions targeting Trp metabolism (like diet or probiotics) may further improve neurobehavioral manifestations including CRF or depression. The gene discussed is KMO; the disease is depressive symptom measurement.